434 related articles for article (PubMed ID: 27979574)
1. Apelin/APJ system: A bifunctional target for cardiac hypertrophy.
Lu L; Wu D; Li L; Chen L
Int J Cardiol; 2017 Mar; 230():164-170. PubMed ID: 27979574
[TBL] [Abstract][Full Text] [Related]
2. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
Parikh VN; Liu J; Shang C; Woods C; Chang AC; Zhao M; Charo DN; Grunwald Z; Huang Y; Seo K; Tsao PS; Bernstein D; Ruiz-Lozano P; Quertermous T; Ashley EA
Am J Physiol Heart Circ Physiol; 2018 Aug; 315(2):H348-H356. PubMed ID: 29775410
[TBL] [Abstract][Full Text] [Related]
3. Apelin/APJ system: A novel promising target for anti-aging intervention.
Zhou Q; Chen L; Tang M; Guo Y; Li L
Clin Chim Acta; 2018 Dec; 487():233-240. PubMed ID: 30296443
[TBL] [Abstract][Full Text] [Related]
4. APJ acts as a dual receptor in cardiac hypertrophy.
Scimia MC; Hurtado C; Ray S; Metzler S; Wei K; Wang J; Woods CE; Purcell NH; Catalucci D; Akasaka T; Bueno OF; Vlasuk GP; Kaliman P; Bodmer R; Smith LH; Ashley E; Mercola M; Brown JH; Ruiz-Lozano P
Nature; 2012 Aug; 488(7411):394-8. PubMed ID: 22810587
[TBL] [Abstract][Full Text] [Related]
5. Apelin/APJ system: A potential therapeutic target for endothelial dysfunction-related diseases.
Cheng J; Luo X; Huang Z; Chen L
J Cell Physiol; 2019 Aug; 234(8):12149-12160. PubMed ID: 30585633
[TBL] [Abstract][Full Text] [Related]
6. Novel pathogenesis: regulation of apoptosis by Apelin/APJ system.
Liu J; Liu M; Chen L
Acta Biochim Biophys Sin (Shanghai); 2017 Jun; 49(6):471-478. PubMed ID: 28407045
[TBL] [Abstract][Full Text] [Related]
7. Apelin/ELABELA-APJ system in cardiac hypertrophy: Regulatory mechanisms and therapeutic potential.
Pang B; Jiang YR; Xu JY; Shao DX; Hao LY
Eur J Pharmacol; 2023 Jun; 949():175727. PubMed ID: 37062502
[TBL] [Abstract][Full Text] [Related]
8. Apelin/APJ system: A critical regulator of vascular smooth muscle cell.
Luo X; Liu J; Zhou H; Chen L
J Cell Physiol; 2018 Jul; 233(7):5180-5188. PubMed ID: 29215755
[TBL] [Abstract][Full Text] [Related]
9. The apelin/APJ system as a therapeutic target in metabolic diseases.
Castan-Laurell I; Masri B; Valet P
Expert Opin Ther Targets; 2019 Mar; 23(3):215-225. PubMed ID: 30570369
[TBL] [Abstract][Full Text] [Related]
10. Apelin/APJ system: A novel therapeutic target for locomotor system diseases.
Luo J; Liu W; Feng F; Chen L
Eur J Pharmacol; 2021 Sep; 906():174286. PubMed ID: 34174264
[TBL] [Abstract][Full Text] [Related]
11. Apelin/APJ system: an emerging therapeutic target for respiratory diseases.
Yan J; Wang A; Cao J; Chen L
Cell Mol Life Sci; 2020 Aug; 77(15):2919-2930. PubMed ID: 32128601
[TBL] [Abstract][Full Text] [Related]
12. Gαi-biased apelin analog protects against isoproterenol-induced myocardial dysfunction in rats.
Coquerel D; Delile E; Dumont L; Chagnon F; Murza A; Sainsily X; Salvail D; Sarret P; Marsault E; Auger-Messier M; Lesur O
Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1646-H1656. PubMed ID: 33635165
[TBL] [Abstract][Full Text] [Related]
13. The apelin/APJ system in the regulation of vascular tone: friend or foe?
Rikitake Y
J Biochem; 2021 Apr; 169(4):383-386. PubMed ID: 33169143
[TBL] [Abstract][Full Text] [Related]
14. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
[TBL] [Abstract][Full Text] [Related]
15. Heterodimerization of apelin and opioid receptors and cardiac inotropic and lusitropic effects of apelin in 2K1C hypertension: Role of pERK1/2 and PKC.
Rostamzadeh F; Najafipour H; Yeganeh-Hajahmadi M; Esmaeili-Mahani S; Joukar S; Iranpour M
Life Sci; 2017 Dec; 191():24-33. PubMed ID: 28987634
[TBL] [Abstract][Full Text] [Related]
16. Lactation Is a Risk Factor of Postpartum Heart Failure in Mice with Cardiomyocyte-specific Apelin Receptor (APJ) Overexpression.
Murata K; Ishida J; Ishimaru T; Mizukami H; Hamada J; Saito C; Fukamizu A
J Biol Chem; 2016 May; 291(21):11241-51. PubMed ID: 27033703
[TBL] [Abstract][Full Text] [Related]
17. Apelin/APJ system as a therapeutic target in diabetes and its complications.
Hu H; He L; Li L; Chen L
Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
[TBL] [Abstract][Full Text] [Related]
18. Apelin/APJ system: an emerging therapeutic target for neurological diseases.
Li A; Zhao Q; Chen L; Li Z
Mol Biol Rep; 2023 Feb; 50(2):1639-1653. PubMed ID: 36378421
[TBL] [Abstract][Full Text] [Related]
19. Apelin and Elabela/Toddler; double ligands for APJ/Apelin receptor in heart development, physiology, and pathology.
Kuba K; Sato T; Imai Y; Yamaguchi T
Peptides; 2019 Jan; 111():62-70. PubMed ID: 29684595
[TBL] [Abstract][Full Text] [Related]
20. (3R)‑5,6,7‑trihydroxy‑3‑isopropyl‑3‑methylisochroman‑1‑one attenuates cardiac dysfunction via the apelin/APJ signaling pathway.
Ding M; Guan L; Zhang C; Yang P; Yang H
Mol Med Rep; 2019 Jun; 19(6):5007-5014. PubMed ID: 30942406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
